Malaria is a life-threatening disease and one of the main causes of morbidity and mortality in the human population. The disease also results in a major socio-economic burden. The rapid spread of
malaria epidemics in developing countries is exacerbated by the rise in drug-resistant parasites and
insecticide-resistant mosquitoes. At present,
malaria research is focused mainly on the development of drugs with increased
therapeutic effects against Plasmodium parasites. However, a
vaccine against the disease is preferable over treatment to achieve long-term control. Trials to develop a safe and effective immunization protocol for the control of
malaria have been occurring for decades, and continue on today; still, no effective
vaccines are available on the market. Recently,
peptide-based
vaccines have become an attractive alternative approach. These
vaccines utilize short
protein fragments to induce immune responses against
malaria parasites.
Peptide-based
vaccines are safer than traditional
vaccines, relatively inexpensive to produce, and can be composed of multiple T- and
B-cell epitopes integrated into one antigenic formulation. Various combinations, based on
antigen choice,
peptide epitope modification and delivery mechanism, have resulted in numerous potential
malaria vaccines candidates; these are presently being studied in both preclinical and clinical trials. This review describes the current landscape of
peptide-based
vaccines, and addresses obstacles and opportunities in the production of
malaria vaccines.